Baird Initiates Coverage On Abbott Laboratories with Outperform Rating, Announces Price Target of $121
Baird analyst David Rescott initiates coverage on Abbott Laboratories (NYSE: ABT ) with a Outperform rating and announces Price Target of $121.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.